ZBIO Stock: Price, Earnings History and SEC Filings
Zenas BioPharma, Inc. (ZBIO) last traded at $28.39, down 1.29% on the latest session and up 5.3% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-1.77 against an analyst estimate of $-0.89, a miss of 98.9%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ZBIO earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 13, 2026 | $-1.77 | $-0.89 | -98.88% |
| Mar 2026 | May 13, 2026 | $-1.46 | $-1.37 | -6.57% |
| Dec 2025 | Mar 16, 2026 | $-4.54 | $-1.22 | -272.13% |
| Sep 2025 | Nov 12, 2025 | $-1.22 | $-0.87 | -40.23% |
ZBIO beat the analyst EPS estimate in 0 of its last 4 reported quarters. Source: Nasdaq.
How ZBIO reacts to earnings
Across its last 8 earnings releases, ZBIO moved 13.8% on average the next session, in either direction. It rose after 5 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-13 | Before open | -6.68% |
| 2026-05-13 | Before open | +4.02% |
| 2026-03-16 | Before open | -3.37% |
| 2026-01-05 | Before open | -51.86% |
| 2025-11-12 | Before open | +1.70% |
| 2025-10-08 | Before open | +24.22% |
| 2025-08-12 | Before open | +6.68% |
| 2025-05-15 | Before open | +12.21% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
ZBIO financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $10M | -$378M | -$172M | -3777.4% | $-8.44 |
| 2024 | $5M | -$157M | -$120M | -3139.8% | $-11.89 |
| 2023 | $50M | -$37M | -$31M | -74.2% | $-24.25 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for ZBIO
- 8-K · Oct 13, 2026Regulation FD disclosure, Financial statements and exhibits
- 10-Q · Aug 13, 2026
- 8-K · Aug 13, 2026Results of operations, Officer or director change, Financial statements and exhibits
- 10-Q · May 13, 2026
- 8-K · May 13, 2026Results of operations, Officer or director change, Shareholder vote
- 8-K · Mar 31, 2026Material agreement, New financial obligation, Other events
- 424B5 · Mar 30, 2026
- 424B5 · Mar 30, 2026
- 424B5 · Mar 26, 2026
- 424B5 · Mar 26, 2026
Insider filing activity
ZBIO insiders filed 1 Form 4 report in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
ZBIO news
- Zenas BioPharma Eyes Key Lupus and IL-17 Data as Obexelimab FDA Decision NearsOct 30, 2026 · marketbeat.com
- Wall Street Analysts Predict a 77.61% Upside in Zenas BioPharma, Inc. (ZBIO): Here's What You Should KnowOct 23, 2026 · finance.yahoo.com
- Zenas BioPharma Stock Gains Attention After Long Term Trial DataOct 21, 2026 · finance.yahoo.com
About Zenas BioPharma, Inc.
Zenas BioPharma, Inc. (ZBIO) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.